Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Slides:

Advertisements

Similar presentations

Biologics in Asthma—The Next Step Toward Personalized Treatment

Advertisements

Pinja Ilmarinen, PhD, Leena E

Advances in Diagnosing Peanut Allergy

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Vitamin D Insufficiency and Asthma in a US Nationwide Study

Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Complementary and Alternative Medicine in Allergy-Immunology: More Information is Needed Leonard Bielory, MD The Journal of Allergy and Clinical Immunology:

Dennis K. Ledford, MD, Sally Wenzel, MD

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Acute and chronic systemic corticosteroid–related complications in patients with severe asthma Patrick Lefebvre, MA, Mei Sheng Duh, MPH, ScD, Marie-Hélène.

Clinical Management of Food Allergy

Badrul A. Chowdhury, MD, PhD

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Steven W. Yancey, MSc, Hector G. Ortega, MD, Oliver N

Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations Kazuto Matsunaga, MD, PhD, Tsunahiko Hirano, MD, PhD,

Comparative Effectiveness of Budesonide-Formoterol Combination and Fluticasone- Salmeterol Combination for Asthma Management: A United States Retrospective.

Journal of Allergy and Clinical Immunology

Reply The Journal of Allergy and Clinical Immunology: In Practice

Kevin Murphy, MD, Joshua Jacobs, MD, Leif Bjermer, MD, John M

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison William Busse, MD, Geoffrey Chupp,

Melkersson-Rosenthal Syndrome

Validation of the Pregnancy Asthma Control Test

Advances in Diagnosing Peanut Allergy

Erythematous Candidiasis

Assessment of Antihistamine Use in Early Pregnancy and Birth Defects

Nonadherence to Asthma Treatment: Getting Unstuck

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Successful treatment of idiopathic angioedema with ecallantide

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management

The HEDIS Medication Management for People with Asthma Measure is Not Related to Improved Asthma Outcomes Angelina Crans Yoon, MD, William Crawford,

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Management of Difficult-to-Treat Atopic Dermatitis

Necdet B. Gunsoy, PhD, Sarah M. Cockle, PhD, Steven W

Repeated Episodes of Anaphylaxis with Normal Serum Tryptase but Elevated Levels of Urinary Prostaglandin D2 Phillip Lieberman, MD The Journal of Allergy.

Penicillin Skin Testing Is a Safe and Effective Tool for Evaluating Penicillin Allergy in the Pediatric Population Stephanie J. Fox, MD, Miguel A. Park,

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12- month follow-up analysis Pranabashis Haldar, MD, Christopher E. Brightling,

Change in Asthma Control Over Time: Predictors and Outcomes

Phillip Lieberman, MD, Michael Tankersley, MD

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Early decreases in blood eosinophil levels with reslizumab

Effects of Mometasone, Fluticasone, and Montelukast on Bone Mineral Density in Adults with Asthma Jorge Maspero, MD, Vibeke Backer, DMSci, MD, Ruji Yao,

News & Notes Journal of Allergy and Clinical Immunology

The Management of Eosinophilic Esophagitis

Phillip Lieberman, MD, David Golden, MD

Melkersson-Rosenthal Syndrome

Anaphylactic Reaction to White-Faced Hornet Sting and Elevated Baseline (Asymptomatic) Serum Tryptase Phillip Lieberman, MD, Lawrence B. Schwartz, MD,

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Mapping the Asthma Care Process: Implications for Research and Practice Alexandra Lelia Dima, PhD, Marijn de Bruin, PhD, Eric Van Ganse, MD, PhD, FRCP

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Cephalosporin Side Chain Cross-reactivity

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS,

Granulomatous-lymphocytic Interstitial Lung Disease in a Patient with Common Variable Immunodeficiency Phil Lieberman, MD, John Routes, MD The Journal.

Sophie F. Demarche, MPharm, Florence N. Schleich, MD, PhD, Virginie A

News & Notes Journal of Allergy and Clinical Immunology

Reply The Journal of Allergy and Clinical Immunology: In Practice

Clinical Management of Atopic Dermatitis: Practical Highlights and Updates from the Atopic Dermatitis Practice Parameter 2012 Peter A. Lio, MD, Margaret.

Footnotes1 Journal of Allergy and Clinical Immunology

Macrolide antibiotics and asthma treatment

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

News & Notes Journal of Allergy and Clinical Immunology

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma Hector Ortega, MD, ScD, Steven W. Yancey, MS, Oliver N. Keene, MS, Necdet B. Gunsoy, PhD, Frank C. Albers, MD, PhD, Peter H. Howarth, MD The Journal of Allergy and Clinical Immunology: In Practice Volume 6, Issue 3, Pages 980-986.e1 (May 2018) DOI: 10.1016/j.jaip.2017.12.019 Copyright © 2018 GlaxoSmithKline Terms and Conditions

Figure 1 Linear trend change in lung function (mL) in a combined DREAM/MENSA analysis. BD, Bronchodilator. Error bars represent 95% CIs. ∗Analysis conducted ≥28 days after an exacerbation. The Journal of Allergy and Clinical Immunology: In Practice 2018 6, 980-986.e1DOI: (10.1016/j.jaip.2017.12.019) Copyright © 2018 GlaxoSmithKline Terms and Conditions

Figure 2 Changes from baseline FEV1 (A) and change from baseline FVC (B) in patients treated with mepolizumab or placebo by number of exacerbations. BD, Bronchodilator. Error bars represent 95% CIs. Difference between groups for changes in FEV1 was statistically significant (P = .040); nonstatistical significant difference between groups for changes in FVC (P = .116). The Journal of Allergy and Clinical Immunology: In Practice 2018 6, 980-986.e1DOI: (10.1016/j.jaip.2017.12.019) Copyright © 2018 GlaxoSmithKline Terms and Conditions